Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Aims To Extend Avastin Duration Of Use

This article was originally published in The Pink Sheet Daily

Executive Summary

Physicians have been treating first-line colorectal cancer patients for less time than the product was used for in clinical trials, Exec VP Clark says.

You may also be interested in...



Roche Files Avastin EU Marketing Authorization Application For NSCLC

An sBLA for the oncologic in non-small cell lung cancer is already pending in the U.S.

Roche Files Avastin EU Marketing Authorization Application For NSCLC

An sBLA for the oncologic in non-small cell lung cancer is already pending in the U.S.

Avastin Approved For Second-Line CRC

Genentech's Avastin gained approval June 20 for use in second-line treatment of metastatic colorectal cancer as an adjunct to chemotherapy, FDA said

Related Content

Topics

UsernamePublicRestriction

Register

PS063990

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel